# PortfolioAI — Program B · B-FINAL Closure

**Checkpoint:** B-FINAL — Program B cross-pipeline closure  
**Date:** 24 September 2026  
**Branch:** `program-a-evidence-coverage`  
**Starting commit:** `5739c9030a9952fffc8f7be1f3afc9462c48ca74`  
**Status:** IMPLEMENTED CANDIDATE — OWNER-LOCAL FINAL VALIDATION PENDING

## 1. Purpose

B-FINAL is a closing regression and audit only.

It introduces no new scoring methodology, recommendation policy, sizing policy,
provider workflow, persistence contract, migration, deployment, merge, scheduler
or trading behavior.

## 2. Checkpoint closure chain

Repository evidence entering B-FINAL:

```text
B0 = COMPLETE / PASS / CLOSED
B1 = COMPLETE / PASS / CLOSED
B2 = COMPLETE / PASS / CLOSED
R6 = COMPLETE / PASS / CLOSED
B3 = COMPLETE / PASS / CLOSED
B4 = COMPLETE / PASS / CLOSED
R7 = COMPLETE / PASS / CLOSED
```

## 3. B-FINAL eleven-point audit

The final audit validates simultaneously:

1. exact R6 -> R7 traceability for every recommendation-ready/sizing-ready result;
2. security + role + assignment lineage preservation;
3. explicit Program B disposition for all 238 frozen K5 equity holdings;
4. deterministic R6 and R7 replay;
5. cross-sector / subprofile / role isolation;
6. Gate H-K shell continuity through inherited regression suites;
7. B1-B4 stop-condition safety boundaries;
8. zero provider calls from Program B compute paths;
9. zero OpenAI numeric-decision calls;
10. zero owner-setting mutation;
11. zero Program B production persistence/deployment/merge/scheduler/trading authority.

## 4. R6 -> R7 traceability

For every recommendation-ready reference, B-FINAL requires exact agreement on:

```text
R6 source score
R6 source-run identity
research parent profile
Primary methodology role/subprofile
assignment version
R7 recommendation-run identity
R7 policy identity/version
downstream sizing source-score/source-recommendation identity
```

Current recommendation-ready reference scope remains:

- TORNTPHARM — `PHARMA_V1 + DOMESTIC_FORMULATIONS`;
- ALIVUS — `PHARMA_V1 + API_BULK_DRUGS`.

No security is currently sizing-ready because Program B has no separately approved
numeric sizing policy.

## 5. Pharma dual-layer invariant

B-FINAL retains the special Pharma architecture:

```text
PHARMA_V1 common parent research
        +
one reviewed Primary subprofile
        ↓
effective Pharma research contract
```

Canonical Primary subprofiles remain exactly:

```text
API_BULK_DRUGS
DOMESTIC_FORMULATIONS
GLOBAL_GENERICS
BIOPHARMA_BIOSIMILARS
CDMO_CRAMS
```

Subprofiles do not replace the parent profile. Secondary exposures/overlays do not
create an independent second stock score or recommendation.

## 6. Portfolio-wide disposition versus numeric coverage

Program B closure deliberately distinguishes:

```text
portfolio-wide disposition complete
!=
portfolio-wide numeric scoring coverage complete
!=
portfolio-wide numeric recommendation coverage complete
!=
portfolio-wide numeric sizing coverage complete
```

B-FINAL requires disposition completeness, not fabricated numeric completeness.

Current intentional limitations remain:

- portfolio-wide numeric scoring coverage is incomplete;
- portfolio-wide numeric recommendation coverage is incomplete;
- no Program B numeric sizing policy is approved;
- the portfolio disposition fixture is the frozen 22 September 2026 K5 snapshot,
  not a live-production 24 September reconciliation.

## 7. Repository safety audit

From B0 closure commit
`10c87a5d9a2eb5338db51f3f85e5f5ce1ff9a605`
through B4 closure commit
`5739c9030a9952fffc8f7be1f3afc9462c48ca74`,
the Program B diff contained 23 changed files and no:

- `supabase/migrations/*` changes;
- `supabase/functions/*` changes;
- deployment/workflow configuration changes.

The Program B branch remains separate from `main`. The branch is therefore a
validated local-candidate development line, not a production deployment state.

The B-FINAL runner adds a strict allowlist guard over Program B's changed files
and fails if migration/provider/deploy surfaces appear.

## 8. Final validation command

Run locally:

```bash
git pull
bash scripts/b-final-validate-program-b.sh
```

The runner performs:

- B-FINAL cross-pipeline audit tests;
- R6/R7 regressions;
- Gate H / G10 reference regressions;
- Pharma parent/subprofile composition and recommendation regressions;
- K5 isolation/routing/portability regressions;
- K3 BANK/NBFC regressions;
- shared BANK benchmark-authority regression;
- D35B sizing software regression;
- owner-decision controls;
- Research / Pharma recommendation UI regressions;
- canonical Program B final report;
- strict Program B repository-change allowlist;
- TypeScript;
- architecture guard;
- production build;
- `git diff --check`.

## 9. Safety boundary

```text
provider calls from Program B compute paths = 0
Angel One calls = 0
Trendlyne calls = 0
OpenAI numeric decision calls = 0
owner settings mutation = 0
recommendation persistence = NO
sizing persistence = NO
production mutation = NO
migration = NO
deployment = NO
merge = NO
scheduler activation = NO
trading = NO
```

## 10. Closure terminology

B-FINAL may close Program B only with:

```text
Program B = COMPLETE / PASS

Portfolio decision pipeline =
VALIDATED / OPERATIONAL IN THE APPROVED LOCAL-CANDIDATE ENVIRONMENT /
FAIL-CLOSED WHERE INCOMPLETE
```

It must **not** be called `PRODUCTION OPERATIONAL`.

Production reconciliation, merge and deployment remain separately gated future
actions.

## 11. Stop boundary

After a clean owner-local B-FINAL validation, Program B may be formally closed.

No next program is authorized by this candidate.
